January 23, 2002
For Immediate Release

Surgical Sealant Market Growth Led by Cyanoacrylates

FOOTHILL RANCH, CA—Cyanoacrylates and other high-strength adhesives comprise the fastest growing segment of the surgical sealants market, according to an article published by MedMarket Diligence in the January 2002 issue of MedMarkets. Much of the growth in the use of cyanoacrylates will result from the need for better closure in topical and internal applications than is afforded by fibrin sealants, whose strength is in hemostasis. The two leading cyanoacrylates are Dermabond (developed by Closure Medical and marketed by Ethicon) and Indermil (developed by Loctite and marketed by Tyco/Sherwood, Davis & Geck).  Other providers of medical-grade cyanoacrylate products targeting this market opportunity include GEM/Biovascular, B. Braun Melsungen, Medlogic Global, Chemence and GluStitch.

“We expect to see a lot of activity in the sealants market in the next few years,” says Patrick Driscoll, President of MedMarket Diligence. “The U.S. market was left behind for most of the ‘90s awaiting FDA approval, but is now being steadily penetrated by these technologies.  According to Driscoll, high strength cyanoacrylates will challenge fibrin products over a broad range of applications, resulting in sales growth for cyanoacrylates and other high-strength sealants at over 25% compounded annually through 2010.

Growth in the other two segments in the $1.6 billion worldwide surgical closure products market, hemostats/fibrin and new synthetic/biological sealants, will be more modest as they have significant competition in their applications, reflected by growth rates of 2.7% and 10%, respectively, according to MedMarkets.

The January issue of MedMarkets also provides coverage and analysis of the 2001 annual meeting of the Radiological Society of North America, discussing key developments in radiofrequency ablation (RFA), computer-assisted diagnosis (CAD), multislice systems and hybrid systems.  Other regular coverage in MedMarkets includes the developments of early stage companies and the host of JV, investment, and other deals shaping the market.

MedMarkets is a monthly publication of MedMarket Diligence, LLC, that analyzes the market implications of new medical technology. MedMarket Diligence provides tactical decision-making solutions on medical technology to the medical products and investment industries.  The company publishes MedMarkets, publishes dedicated reports on technology markets, and is developing other information solutions.  For more information on MedMarket Diligence, LLC, contact Patrick Driscoll at (949) 859-3401, e-mail, or visit the Web site at http://www.mediligence.com to view a sample issue of MedMarkets.

 Contact: Patrick Driscoll, (949) 859-3401.